Aurobindo Pharma Limited (AUROPHARMA) - Net Assets

Latest as of September 2025: Rs350.34 Billion INR ≈ $3.79 Billion USD

Based on the latest financial reports, Aurobindo Pharma Limited (AUROPHARMA) has net assets worth Rs350.34 Billion INR (≈ $3.79 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs525.46 Billion ≈ $5.68 Billion USD) and total liabilities (Rs175.12 Billion ≈ $1.89 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Aurobindo Pharma Limited (AUROPHARMA) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs350.34 Billion
% of Total Assets	66.67%
Annual Growth Rate	19.88%
5-Year Change	48.88%
10-Year Change	378.85%
Growth Volatility	14.04

Aurobindo Pharma Limited - Net Assets Trend (2004–2025)

This chart illustrates how Aurobindo Pharma Limited's net assets have evolved over time, based on quarterly financial data. Also explore how large is Aurobindo Pharma Limited's balance sheet for the complete picture of this company's asset base.

Annual Net Assets for Aurobindo Pharma Limited (2004–2025)

The table below shows the annual net assets of Aurobindo Pharma Limited from 2004 to 2025. For live valuation and market cap data, see Aurobindo Pharma Limited (AUROPHARMA) market capitalisation.

Year	Net Assets	Change
2025-03-31	Rs326.47 Billion ≈ $3.53 Billion	+9.37%
2024-03-31	Rs298.51 Billion ≈ $3.23 Billion	+11.17%
2023-03-31	Rs268.52 Billion ≈ $2.90 Billion	+9.27%
2022-03-31	Rs245.74 Billion ≈ $2.66 Billion	+12.06%
2021-03-31	Rs219.29 Billion ≈ $2.37 Billion	+30.34%
2020-03-31	Rs168.25 Billion ≈ $1.82 Billion	+21.11%
2019-03-31	Rs138.92 Billion ≈ $1.50 Billion	+18.92%
2018-03-31	Rs116.82 Billion ≈ $1.26 Billion	+24.62%
2017-03-31	Rs93.74 Billion ≈ $1.01 Billion	+37.49%
2016-03-31	Rs68.18 Billion ≈ $737.31 Million	+31.57%
2015-03-31	Rs51.82 Billion ≈ $560.38 Million	+37.23%
2014-03-31	Rs37.76 Billion ≈ $408.34 Million	+44.02%
2013-03-31	Rs26.22 Billion ≈ $283.53 Million	+11.57%
2012-03-31	Rs23.50 Billion ≈ $254.13 Million	-4.05%
2011-03-31	Rs24.49 Billion ≈ $264.85 Million	+33.58%
2010-03-31	Rs18.33 Billion ≈ $198.28 Million	+47.33%
2009-03-31	Rs12.44 Billion ≈ $134.58 Million	+10.39%
2008-03-31	Rs11.27 Billion ≈ $121.91 Million	+26.72%
2007-03-31	Rs8.90 Billion ≈ $96.20 Million	+8.84%
2006-03-31	Rs8.17 Billion ≈ $88.39 Million	+14.39%
2005-03-31	Rs7.14 Billion ≈ $77.27 Million	-1.45%
2004-03-31	Rs7.25 Billion ≈ $78.40 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Aurobindo Pharma Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 30221650000000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component	Amount	Percentage
Retained Earnings	Rs302.22 Billion	92.55%
Common Stock	Rs580.80 Million	0.18%
Other Comprehensive Income	Rs22.98 Billion	7.04%
Other Components	Rs751.10 Million	0.23%
Total Equity	Rs326.53 Billion	100.00%

Aurobindo Pharma Limited Competitors by Market Cap

The table below lists competitors of Aurobindo Pharma Limited ranked by their market capitalization.

Company	Market Cap
Rainbow Robotics Inc. KQ:277810	$8.73 Billion
Aurora Innovation Inc NASDAQ:AUR	$8.73 Billion
Grupo Aeroportuario del Sureste SAB de CV ADR NYSE:ASR	$8.73 Billion
Owens Corning Inc NYSE:OC	$8.73 Billion
Realtek Semiconductor Corp TW:2379	$8.72 Billion
Samsung SDS Co Ltd KO:018260	$8.71 Billion
The Lottery Corporation Ltd AU:TLC	$8.71 Billion
Henry Schein Inc NASDAQ:HSIC	$8.70 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Aurobindo Pharma Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 298,428,000,000 to 326,533,200,000, a change of 28,105,200,000 (9.4%).
Net income of 34,858,800,000 contributed positively to equity growth.
Dividend payments of 10,400,000 reduced retained earnings.
Share repurchases of 9,302,400,000 reduced equity.
Other comprehensive income decreased equity by 2,664,200,000.
Other factors increased equity by 5,223,400,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Rs34.86 Billion	+10.68%
Dividends Paid	Rs10.40 Million	-0.0%
Share Repurchases	Rs9.30 Billion	-2.85%
Other Comprehensive Income	Rs-2.66 Billion	-0.82%
Other Changes	Rs5.22 Billion	+1.6%
Total Change	Rs-	9.42%

Book Value vs Market Value Analysis

This analysis compares Aurobindo Pharma Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.48x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 92.29x to 2.48x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2004-03-31	Rs15.06	Rs1389.50	x
2005-03-31	Rs14.05	Rs1389.50	x
2006-03-31	Rs14.64	Rs1389.50	x
2007-03-31	Rs13.35	Rs1389.50	x
2008-03-31	Rs16.65	Rs1389.50	x
2009-03-31	Rs19.17	Rs1389.50	x
2010-03-31	Rs28.93	Rs1389.50	x
2011-03-31	Rs38.20	Rs1389.50	x
2012-03-31	Rs40.18	Rs1389.50	x
2013-03-31	Rs44.72	Rs1389.50	x
2014-03-31	Rs64.24	Rs1389.50	x
2015-03-31	Rs88.32	Rs1389.50	x
2016-03-31	Rs120.77	Rs1389.50	x
2017-03-31	Rs160.14	Rs1389.50	x
2018-03-31	Rs199.35	Rs1389.50	x
2019-03-31	Rs237.07	Rs1389.50	x
2020-03-31	Rs287.14	Rs1389.50	x
2021-03-31	Rs374.27	Rs1389.50	x
2022-03-31	Rs419.43	Rs1389.50	x
2023-03-31	Rs458.07	Rs1389.50	x
2024-03-31	Rs509.32	Rs1389.50	x
2025-03-31	Rs560.22	Rs1389.50	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Aurobindo Pharma Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 10.68%
The company shows good efficiency in utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 10.99%
• Asset Turnover: 0.64x
• Equity Multiplier: 1.52x
Recent ROE (10.68%) is below the historical average (17.26%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2004	15.01%	7.22%	0.81x	2.58x	Rs362.62 Million
2005	0.46%	0.25%	0.62x	2.99x	Rs-680.74 Million
2006	8.55%	4.37%	0.59x	3.30x	Rs-117.87 Million
2007	22.68%	9.47%	0.61x	3.96x	Rs1.12 Billion
2008	21.22%	9.79%	0.67x	3.23x	Rs1.26 Billion
2009	8.08%	3.26%	0.73x	3.40x	Rs-238.66 Million
2010	30.67%	15.69%	0.75x	2.62x	Rs3.78 Billion
2011	23.05%	12.86%	0.75x	2.40x	Rs3.19 Billion
2012	-5.28%	-2.72%	0.73x	2.67x	Rs-3.57 Billion
2013	11.28%	5.00%	0.81x	2.79x	Rs332.84 Million
2014	42.02%	12.99%	1.28x	2.53x	Rs12.01 Billion
2015	30.56%	12.99%	0.94x	2.50x	Rs10.60 Billion
2016	28.70%	14.66%	0.87x	2.26x	Rs13.19 Billion
2017	24.56%	15.41%	0.92x	1.73x	Rs13.64 Billion
2018	20.75%	14.72%	0.78x	1.81x	Rs12.55 Billion
2019	17.02%	12.09%	0.74x	1.90x	Rs9.76 Billion
2020	16.91%	12.32%	0.80x	1.72x	Rs11.63 Billion
2021	24.33%	21.53%	0.73x	1.54x	Rs31.42 Billion
2022	10.78%	11.29%	0.69x	1.38x	Rs1.91 Billion
2023	7.18%	7.75%	0.62x	1.49x	Rs-7.56 Billion
2024	10.63%	10.94%	0.64x	1.51x	Rs1.89 Billion
2025	10.68%	10.99%	0.64x	1.52x	Rs2.21 Billion

Industry Comparison

This section compares Aurobindo Pharma Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $23,737,158,958
Average return on equity (ROE) among peers: 10.38%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Aurobindo Pharma Limited (AUROPHARMA)	Rs350.34 Billion	15.01%	0.50x	$8.73 Billion
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$988.60 Million	6.59%	1.36x	$27.93 Million
Aarti Drugs Limited (AARTIDRUGS)	$6.52 Billion	21.67%	1.42x	$371.43 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$19.90 Billion	13.69%	0.46x	$725.68 Million
Abbott India Limited (ABBOTINDIA)	$36.99 Billion	32.48%	0.40x	$5.85 Billion
Ajanta Pharma Limited (AJANTPHARM)	$1.16 Billion	12.69%	1.32x	$3.81 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$6.25 Billion	-40.39%	3.91x	$906.19 Million
Alkem Laboratories Limited (ALKEM)	$88.47 Billion	18.60%	0.59x	$6.98 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$1.46 Billion	16.82%	0.29x	$178.52 Million
Alembic Pharmaceuticals Limited (APLLTD)	$51.90 Billion	11.24%	0.50x	$1.60 Billion

About Aurobindo Pharma Limited

NSE:AUROPHARMA India Drug Manufacturers - Specialty & Generic

Market Cap

$8.73 Billion

Rs807.02 Billion INR

Market Cap Rank

#2469 Global

#98 in India

Share Price

Rs1389.50

Change (1 day)

-0.52%

52-Week Range

Rs1022.20 - Rs1435.40

All Time High

Rs1568.05